These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9096705)

  • 21. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
    Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
    Bonifazi F; de Vivo A; Rosti G; Guilhot F; Guilhot J; Trabacchi E; Hehlmann R; Hochhaus A; Shepherd PC; Steegmann JL; Kluin-Nelemans HC; Thaler J; Simonsson B; Louwagie A; Reiffers J; Mahon FX; Montefusco E; Alimena G; Hasford J; Richards S; Saglio G; Testoni N; Martinelli G; Tura S; Baccarani M; ; ; ; ; ; ; ;
    Blood; 2001 Nov; 98(10):3074-81. PubMed ID: 11698293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
    Talwar R; Choudhry VP; Jobanputra V; Kucheria K
    Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
    Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
    Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular remission achieved by interferon therapy in a patient with cytogenetically relapsed chronic myelogenous leukemia after syngeneic bone marrow transplantation.
    Yano K; Iijima K; Sao H; Kobayashi M
    Int J Hematol; 1996 Oct; 64(3-4):267-70. PubMed ID: 8923790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
    Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
    Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA].
    Casado LF; Steegmann JL; Picó M; Requena MJ; Gómez C; Fernández-Rañada JM
    Sangre (Barc); 1995 Oct; 40(5):417-20. PubMed ID: 8553177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.
    Duba HC; Peter S; Hilbe W; Fluckinger T; Fridrik M; Erdel M; Thaler J; Utermann G
    Int J Oncol; 1999 Jan; 14(1):145-50. PubMed ID: 9863021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.
    Kloke O; Niederle N; Qiu JY; Wandl U; Moritz T; Nagel-Hiemke M; Hawig I; Opalka B; Seeber S; Becher R
    Br J Haematol; 1993 Mar; 83(3):399-403. PubMed ID: 8485045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
    Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia.
    Egyed M; Kollár B; Rumi G; Keller E; Vass J; Fekete S
    Acta Haematol; 2003; 109(2):84-9. PubMed ID: 12624492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.